Paxlovid Gets FDA Panel Backing For Full Approval; Combating Rebound Misperception Urged
Executive Summary
Patient advocate is sole committee member to vote against Paxlovid favorable benefit-risk profile, saying doctors do not know how to use the treatment. Members suggest conducting natural history studies on COVID rebound and publishing data that shows no clear association with Paxlovid.